Glenmark Pharma US Launches Leucovorin Calcium Injection – Key Oncology Boost

Glenmark's US subsidiary strengthens its institutional offerings with Leucovorin Calcium for Injection USP, 350 mg/vial, a critical adjunct in chemotherapy regimens like methotrexate rescue and colorectal cancer protocols with 5-FU.

The product, deemed bioequivalent by FDA standards, enters a market vital for hospitals treating high-risk patients, building on Glenmark's recent injectables like Sodium Bicarbonate and Ropivacaine.​

This launch aligns with Glenmark's aggressive US generics strategy, targeting $100M+ annual segments amid oncology demand surge.

Key Highlights:

Product Specs: Leucovorin Calcium 350 mg/vial, single-dose for IV use.​

Launch Timeline: Commercial rollout December 2025 via institutional channels.​

Therapeutic Role: Methotrexate antidote, enhances 5-FU efficacy in cancer care.​

Portfolio Fit: Bolsters Glenmark's 50+ US injectables, focusing hospital supply.​

Market Impact: Addresses shortages, supports affordable access in oncology.​

Sources: Business Upturn, Glenmark Pharma US Newsroom, Business Standard.​